The Exchange had sought clarification from Nectar Lifesciences Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1.Financial results submitted is not as per format prescribed by SEBI The response of the Company is enclosed.
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The NSE had asked Nectar Lifesciences to clarify why its financial results for the quarter ended 30 September 2025 were not submitted in the format prescribed by SEBI under Regulation 33 of the Listing Regulations. The company has now submitted its response, which is enclosed with the filing. No specific financial details, penalties, or quantitative disclosures are mentioned in this announcement. The filing is purely procedural and relates to the presentation format of an already-submitted results document.
This is a routine compliance clarification and does not indicate any financial or governance trouble. Investors are unlikely to see any meaningful impact on the stock price, though it reflects minor delays in proper submission format.